Association of HPV and sexually transmitted infections among patients with genital warts and asymptomatic individuals: a cross-sectional study

STIs can impact HPV infection and persistence, potentially predisposing HPV-related cervical cancer development. This study examines HPV genotype prevalence and co-occurrence with other STIs to inform targeted prevention and treatment strategies for reducing cervical cancer incidence. 129 female patients aged 18–57 were enrolled based on the presence of anogenital warts, individuals with a history of risky sexual behaviors, having a partner with HPV infection, or voluntarily seeking HPV screening. Patients with a history of any STIs, prior HPV vaccination, systemic illnesses, or undergoing cancer treatment were excluded. Patients were divided into two groups: Genital warts group (31.8%) and asymptomatic group (68.2%). Among patients with genital warts, HPV types 6, 11, and 61 were prevalent, whereas in asymptomatic patients, HPV types 53, 31, and 16 were more common. The STI positivity rate among HPV-positive patients was 63.9%, significantly higher than HPV-negative cases. In the genital warts group at admission, Ureaplasma Parvum (UP) was the most common STI (40.0%), followed by Uraeplasma Urealyticum (UU) (28.5%), Mycoplasma Hominis (MH) (17.2%), and Chlamidia Trachomatis (CT) (11.4%). In the asymptomatic group, UP was also the most common STI (41.2%), followed by UU (17.6%), MH (15.8%), CT (9.7%), TV (6.2%), MG (5.3%), HSV-2 (2.6%), TP (0.8%), and NG (0.8%). The prevalence of UP was significantly higher (53.7%) in the HPV-positive group, suggesting a 6.96-fold greater risk of UP infection in individuals with HPV. This study demonstrates a high co-infection rate between HPV and UP, emphasizing the importance of genital infection screening for high-risk HPV-positive women. Further longitudinal research is needed to investigate the role of STIs as contributing factors in HPV-related cervical cancer development.

HPV genotypes; STI co-infections; Ureaplasma parvum; Cervical infections; Cervical cancer risk

[1] Van Gerwen OT, Muzny CA, Marrazzo JM. Sexually transmitted infections and female reproductive health. Nature Microbiology. 2022; 7: 1116–1126.

[2] Centers for Disease Control and Prevention. Human Papillomavirus (HPV) Statistics. 2021. Available at: https://www.cdc.gov/std/hpv/stats.htm (Accessed: 11 May 2023).

[3] Ntanasis-Stathopoulos I, Kyriazoglou A, Liontos M, A Dimopoulos M, Gavriatopoulou M. Current trends in the management and prevention of human papillomavirus (HPV) infection. Journal of BUON. 2020; 25: 1281–1285.

[4] Brancaccio RN, Robitaille A, Dutta S, Cuenin C, Santare D, Skenders G, et al. Generation of a novel next-generation sequencing-based method for the isolation of new human papillomavirus types. Virology. 2018; 520: 1–10.

[5] Centers for Disease Control and Prevention. CDC Report on Human Papillomavirus (HPV). 2022. Available at: https://www.cdc.gov/cancer/hpv/basic_info/index.htm (Accessed: 11 May 2023).

[6] Kombe Kombe AJ, Li B, Zahid A, Mengist HM, Bounda G-A, Zhou Y, et al. Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. Frontiers in Public Health. 2021; 8: 552028.

[7] Small W Jr, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, et al. Cervical cancer: a global health crisis. Cancer. 2017; 123: 2404–2412.

[8] Tamim H, Finan RR, Sharida HE, Rashid M, Almawi WY. Cervicovagi-nal coinfections with human papillomavirus and chlamydia trachomatis. Diagnostic Microbiology and Infectious Disease. 2002; 43: 277–281.

[9] Carneiro FP, Darós AC, Darós ACM, de Castro TMML, de Vasconcelos Carneiro M, Fidelis CR, et al. Cervical cytology of samples with ureaplasma urealyticum, ureaplasma parvum, chlamydia trachomatis, trichomonas vaginalis, mycoplasma hominis, and neisseria gonorrhoeae detected by multiplex PCR. BioMed Research International. 2020; 2020: 7045217.

[10] Brotman RM, Shardell MD, Gajer P, Fadrosh D, Chang K, Silver MI, et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2014; 21: 450–458.

[11] Watts DH, Fazzari M, Minkoff H, Hillier SL, Sha B, Glesby M, et al. Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. The Journal of Infectious Diseases. 2005; 191: 1129–1139.

[12] Borgdorff H, Tsivtsivadze E, Verhelst R, Marzorati M, Jurriaans S, Ndayisaba GF, et al. Lactobacillus-dominated cervicovaginal microbiota associated with reduced HIV/STI prevalence and genital HIV viral load in African women. The ISME Journal. 2014; 8: 1781–1793.

[13] Tekalegn Y, Sahiledengle B, Woldeyohannes D, Atlaw D, Degno S, Desta F, et al. High parity is associated with increased risk of cervical cancer: Systematic review and meta-analysis of case-control studies. Women’S Health. 2022; 18: 17455065221075904.

[14] Zhu B, Tao Z, Edupuganti L, Serrano MG, Buck GA. Roles of the microbiota of the female reproductive tract in gynecological and reproductive health. Microbiology and Molecular Biology Reviews. 2022; 86: e0018121.

[15] AB ANALYTICA Advanced Biomedicine. AMPLIQUALITY HPV-TYPE EXPRESS v3.0 Technical leaflet. 2023. Available at: https://www.abanalitica.com/en/catalogo/product/ampliquality-hpv-type-express-v30/ (Accessed: 11 May 2023).

[16] Anatolia Geneworks. Bosphore STDs Panel Kit v6 Technical leaflet. 2023. Available at: https://www.anatoliageneworks.com/en/kits/panel-kits/std-panel/ (Accessed: 11 May 2023).

[17] Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infectious Diseases. 2013; 13: 39.

[18] Wang W, Kothari S, Baay M, Garland SM, Giuliano AR, Nygård M, et al. Real-world impact and effectiveness assessment of the quadrivalent HPV vaccine: a systematic review of study designs and data sources. Expert Review of Vaccines. 2022; 21: 227–240.

[19] Raçi PZ, Hošnjak L, Poljak M, Lepej SŽ, Vince A. Pre-vaccination prevalence of high-risk human papillomaviruses (HPV) in women from Kosovo and their related sociodemographic characteristics. Ginekologia Polska. 2018; 89: 485–494.

[20] Gultekin M, Zayifoglu Karaca M, Kucukyildiz I, Dundar S, Boztas G, Semra Turan H, et al. Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women. International Journal of Cancer. 2018; 142: 1952–1958.

[21] Martinelli M, Musumeci R, Sechi I, Sotgiu G, Piana A, Perdoni F, et al. Prevalence of human papillomavirus (HPV) and other sexually transmitted infections (STIs) among Italian women referred for a colposcopy. International Journal of Environmental Research and Public Health. 2019; 16: 5000.

[22] Zhu C, Wang Y, Mao W, Zhang H, Ma J. Prevalence and distribution of HPV types in genital warts in Xi’an, China: a prospective study. BMJ Open. 2019; 9: e023897.

[23] Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. The Journal of Infectious Diseases. 2010; 202: 1789–1799.

[24] Mortaki D, Tsitsopoulos E, Louizou E, Tsiambas E, Peschos D, Sioulas V, et al. Prevalence of cervico-vaginal high-risk HPV types and other sexually transmitted pathogens in anogenital warts patients. Anticancer Research. 2020; 40: 2219–2223.

[25] Kataja V, Syrjänen S, Yliskoski M, Hippeläinen M, Väyrynen M, Saarikoski S, et al. Risk factors associated with cervical human papillomavirus infections: a case-control study. American Journal of Epidemiology. 1993; 138: 735–745.

[26] Zhu H, Shen Z, Luo H, Zhang W, Zhu X. Chlamydia trachomatis infection-associated risk of cervical cancer. Medicine. 2016; 95: e3077.

[27] Kero K, Rautava J, Syrjänen K, Grenman S, Syrjänen S. Association of asymptomatic bacterial vaginosis with persistence of female genital hu-man papillomavirus infection. European Journal of Clinical Microbiology & Infectious Diseases. 2017; 36: 2215–2219.

[28] Biernat-Sudolska M, Szostek S, Rojek-Zakrzewska D, Klimek M, Kosz-Vnenchak M. Concomitant infections with human papillomavirus and various mycoplasma and ureaplsasma species in women with abnormal cervical cytology. Advances in Medical Sciences. 2011; 56: 299–303.

[29] Wang K, Muñoz KJ, Tan M, Sütterlin C. Chlamydia and HPV induce centrosome amplification in the host cell through additive mechanisms. Cellular Microbiology. 2021; 23: e13397.

[30] Horner P, Donders G, Cusini M, Gomberg M, Jensen JS, Unemo M. Should we be testing for urogenital mycoplasma hominis, ureaplasma parvum and ureaplasma urealyticum in men and women?—a position statement from the European STI guidelines editorial board. Journal of the European Academy of Dermatology and Venereology. 2018; 32: 1845–1851.

[31] Weissenbacher T, Walter C, Mylonas I, Scholz C, Gingelmaier A, Friese K. Interleukin-6, interleukin-10 and interleukin-12 in vaginal fluid from women with bacterial vaginosis. Archives of Gynecology and Obstetrics. 2010; 281: 77–80.

[32] Liang Y, Chen M, Qin L, Wan B, Wang H. A meta-analysis of the relationship between vaginal microecology, human papillomavirus infection and cervical intraepithelial neoplasia. Infectious Agents and Cancer. 2019; 14: 29.

[33] Lu H, Jiang PC, Zhang XD, Hou WJ, Wei ZH, Lu JQ, et al. Characteristics of bacterial vaginosis infection in cervical lesions with high risk human papillomavirus infection. International Journal of Clinical and Experimental Medicine. 2015; 8: 21080–21088.

[34] Ward H, Rönn M. The contribution of STIs to the sexual transmission of HIV. Current Opinion in HIV and AIDS. 2010; 5: 305–310.

[35] Hocking JS, Geisler WM, Kong FYS. Update on the epidemiology, screening, and management of chlamydia trachomatis infection. Infec-tious Disease Clinics of North America. 2023; 37: 267–288.

[36] Unemo M, Bradshaw CS, Hocking JS, de Vries HJC, Francis SC, Mabey D, et al. Sexually transmitted infections: challenges ahead. The Lancet Infectious Diseases. 2017; 17: e235–e279.